Myelin oligodendrocyte glycoprotein antibody-associated bilateral optic neuritis with unilateral prepapillary vitreous hemorrhage

Joel Mudri; Richard Warne; Jane Lock; Snehal Shah

doi:10.1016/j.jaapos.2022.02.007

Myelin oligodendrocyte glycoprotein antibody-associated bilateral optic neuritis with unilateral prepapillary vitreous hemorrhage

J AAPOS. 2022 Jun;26(3):161-164. doi: 10.1016/j.jaapos.2022.02.007. Epub 2022 May 4.

Authors

Joel Mudri¹, Richard Warne², Jane Lock³, Snehal Shah⁴

Affiliations

¹ Department of Ophthalmology, Fremantle Hospital, Perth WA Australia. Electronic address: joel.mudri@health.wa.gov.au.
² Department of Medical Imaging, Perth Children's Hospital WA Australia.
³ Department of Ophthalmology, Perth Children's Hospital WA Australia; Department of Ophthalmology, Royal Perth Hospital, Perth WA Australia; Department of Ophthalmology, Sir Charles Gairdner Hospital, Perth WA Australia.
⁴ Department of Neurology, Perth Children's Hospital, Perth WA Australia; The University of Western Australia.

PMID: 35525384
DOI: 10.1016/j.jaapos.2022.02.007

Abstract

We present a case of bilateral myelin oligodendrocyte glycoprotein antibody optic neuritis (MOG-ON) with unilateral vitreous hemorrhage in a 6-year-old boy. Multidisciplinary team care, including extensive investigations and prolonged follow-up, excluded alternative causes of vitreous hemorrhage. Early suspicion and diagnosis of MOG-ON led to timely intravenous methylprednisolone treatment, with protracted oral steroid taper, resulting in complete resolution of optic nerve swelling, vitreous hemorrhage, and visual function.

Publication types

Case Reports

MeSH terms

Autoantibodies
Humans
Methylprednisolone / therapeutic use
Myelin-Oligodendrocyte Glycoprotein
Optic Neuritis* / diagnosis
Optic Neuritis* / drug therapy
Vitreous Hemorrhage* / diagnosis
Vitreous Hemorrhage* / drug therapy
Vitreous Hemorrhage* / etiology

Substances

Autoantibodies
Myelin-Oligodendrocyte Glycoprotein
Methylprednisolone